Le Lézard
Classified in: Health
Subjects: PDT, TRI

Vascular Graft Solutions Reports the First Clinical Use of Its FRAME External Support Technology in Aneurysm Repair of High Flow Arteriovenous Fistulas


TEL AVIV, Israel, Aug. 20, 2018 /PRNewswire/ -- Vascular Graft Solutions reports the first clinical use of its FRAME external support technology for aneurysm repair in high flow arteriovenous (AV) fistulas. The first 5 cases were performed by Dr. Vladimir Matoussevitch from Cologne University Hospital in Germany.

Dr. Vladimir Matoussevitch, Cologne University Hospital

"Autogenous AV fistula access for hemodialysis is a routine surgical procedure," said Dr. Matoussevitch. "However, development of high flow AV fistula and aneurysmal enlargement are not uncommon complications with severe clinical and cosmetic impact on patients. High flow AV access increases cardiac output, which may lead to eccentric left ventricular hypertrophy, a key factor in the development of congestive heart failure in hemodialysis patients. In addition, aneurysmal enlargements are at high risk to develop active bleeding, rupture and infection."

FRAME is a CE marked, kink resistant, cobalt chromium external support indicated for peripheral arterial bypass and reconstructions surgeries. In AV fistula reconstruction surgery, the aneurysm sac is resected and the vein diameter is reduced to 5-6mm. After downsizing, FRAME was applied over the repaired vein to prevent future dilatation and recurrence of aneurysm. Limiting the AV fistula outflow with FRAME, may also prevent development of high flow fistula and heart failure.

"FRAME is a simple and elegant tool that takes minutes to implant and has the potential to prevent serious clinical complications," continued Dr. Matoussevitch. "In the initial cohort of high flow fistulas, we treated so far, the post procedure flow was reduced dramatically. I am looking forward to expand our knowledge about this new technique and its effect on hemodialysis patients."

"We would like to thank Dr. Matoussevitch for leading this innovative approach of treating high flow fistulas with FRAME technology," said Dr. Eyal Orion, founder and CEO of VGS. "To date, FRAME was used with great success in different peripheral reconstruction procedures that required support of venous segments. We are looking forward to working together with vascular surgeons to expand our experience with FRAME."

Contact:
Rotem Katzenellenbogen
VP Business Development
[email protected]
+972-3549-9054

 

SOURCE Vascular Grafts Solutions


These press releases may also interest you

at 07:45
Sensi.AI, a leader in AI-native, data, and analytics in senior care, today announced the appointment of in-home care leader Bob Roth to its Advisory Board. This partnership is an exciting validation of Sensi.AI's promise to enhance proactive,...

at 07:05
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...

at 07:05
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...

at 07:04
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of  KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...

at 07:00
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024.  At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...

at 07:00
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...



News published on and distributed by: